ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2017 and provided an update on the Company's recent developments.

Click here to see the full Press Release